Epizyme reported $124.52M in Cash and Equivalent for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agios Pharmaceuticals AGIO:US $ 400.22M 568.9M
Amarin AMRN:US $ 222.88M 104.14M
Amgen AMGN:US $ 11969M 5339M
Avrobio Inc AVRO:US $ 201.37M 25.07M
Biogen BIIB:US $ 1541.8M 200.2M
Bluebird Bio BLUE:US $ 402.46M 48.99M
Cerulean Pharma CERU:US $ 45.57M 36.46M
Daiichi Sankyo 4568:JP Y 550054M 197792M
Eisai 4523:JP Y 283002M 69920M
Epizyme EPZM:US $ 124.52M 44.35M
Exelixis EXEL:US $ 567.33M 74.86M
Gilead Sciences GILD:US $ 6837M 1944M
Glaxosmithkline GSK:US $ 3453M 50M
GlaxoSmithKline GSK:LN 3453M 50M
Karyopharm Therapeutics KPTI:US $ 137.4M 3.91M
Macrogenics MGNX:US $ 190.53M 1.56M
Mirati Therapeutics MRTX:US $ 176.78M 82.21M
Novartis NOVN:VX SF 7211M 2094M
Novartis NVS:US $ 7211M 2094M
Regeneron Pharmaceuticals REGN:US $ 3432.4M 1360.2M
Seattle Genetics SGEN:US $ 685.17M 271.74M
Spectrum Pharmaceuticals SPPI:US $ 107.44M 7.14M
Vertex Pharmaceuticals VRTX:US $ 6275.7M 212.02M
Xencor XNCR:US $ 41.2M 74.64M